

DRUG NAME: Cyclophosphamide**SYNONYM:** Cyclo, CPA, CPM, CTX, CYC, CYT**COMMON TRADE NAME:** CYTOXAN®,¹ PROCYTOX®, NEOSAR® (USA)**CLASSIFICATION:** Alkylating agent*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Cyclophosphamide is an alkylating agent of the nitrogen mustard type.² An activated form of cyclophosphamide, phosphoramidate mustard, alkylates, or binds, to DNA. Its cytotoxic effect is mainly due to cross-linking of strands of DNA and RNA, and to inhibition of protein synthesis.³ These actions do not appear to be cell-cycle specific.

PHARMACOKINETICS:

Interpatient variability	metabolism; clearance of cyclophosphamide and its metabolites ⁴	
Oral Absorption	>75% ² ; manufacturer recommends drug be taken on an empty stomach, but states may be taken with food to decrease GI upset ⁵	
	time to peak plasma concentration	1-2 h ³
Distribution	throughout body	
	cross blood brain barrier?	to limited extent ²
	volume of distribution	0.56 L/kg ⁶
	plasma protein binding ⁷	12-14% of unchanged drug; 67% of total plasma alkylating metabolites ⁶
Metabolism	mainly by microsomal enzymes in the liver; ⁸ cytochrome P450 (CYP) primarily CYP 2B6 ⁹	
	active metabolites ⁴	4-hydroxycyclophosphamide, aldophosphamide, phosphoramidate mustard, acrolein ¹⁰
	inactive metabolites ⁴	4-keto-cyclophosphamide, carboxyphosphamide, normitrogen mustard
Excretion	primarily by enzymatic oxidation to active and inactive metabolites, which are mainly excreted in the urine ⁷	
	urine	5-25% unchanged ²
	feces	31-66% after oral dose
	terminal half life ⁷	6.5 h (1.8-12.4 h)
	clearance ⁷	1.17 mL/min/kg
Gender	no clinically important differences found	
Elderly	no clinically important differences found	
Children	terminal half life 2.4-6.5 h ⁷ ; volume of distribution 0.67 L/kg ⁷	
Ethnicity	no clinically important differences found	

Adapted from standard reference¹¹ unless specified otherwise.

USES:**Primary uses:**

*Breast cancer
 Conditioning regimen for stem cell transplant
 Ewing's sarcoma
 *Leukemia, acute myelogenous
 *Leukemia, chronic lymphocytic
 *Leukemia, chronic myelogenous
 *Leukemia, pediatric acute lymphoblastic
 *Lung cancer
 *Lymphoma, Burkitt's
 *Lymphoma, Hodgkin's disease
 *Lymphoma, non-Hodgkin's
 Lymphoproliferative disease
 *Multiple myeloma
 *Mycosis fungoides
 *Neuroblastoma
 *Ovarian cancer
 *Retinoblastoma
 Rhabdomyosarcoma

*Health Canada approved indication

Other uses:

Bladder cancer¹²
 Brain cancer¹²
 Cervical cancer¹²
 Endometrial cancer¹¹
 Gestational trophoblastic neoplasia¹²
 Leukemia, acute lymphocytic¹²
 Lymphoma, cutaneous T-cell¹¹
 Osteosarcoma¹²
 Soft tissue sarcoma¹²
 Testicular cancer¹²
 Thymoma¹²
 Waldenstrom's macroglobulinemia¹²
 Wilm's tumour¹¹

SPECIAL PRECAUTIONS:

Contraindicated in patients who have a history of hypersensitivity reaction to cyclophosphamide.² There is possible cross-sensitivity with other alkylating agents.¹

Carcinogenicity: Secondary malignancies have developed in patients treated with cyclophosphamide alone or in combination with other antineoplastics. Occurring most frequently are bladder, myeloproliferative and lymphoproliferative malignancies. Secondary malignancies are most common in patients treated initially for myeloproliferative or lymphoproliferative diseases or for non-malignant conditions with immune pathology. Urinary bladder malignancies are most common in patients who experienced hemorrhagic cystitis.

Mutagenicity: Because of the mutagenic potential of cyclophosphamide, adequate methods of contraception should be used by patients (both male and female) during and at least four months after treatment.¹

Fertility: Gonadal suppression may occur and sterility can be irreversible in some patients.² Age and duration of chemotherapy are the main factors contributing to ovarian failure.¹³ For example, treatment with cyclophosphamide, methotrexate and fluorouracil for six months results in permanent ovarian failure in 70 percent of women over 40 years of age and in 40 percent of younger women. The median time to onset of ovarian failure is shorter in older women than in younger women (2-4 months vs. 6-16 months), and ovarian failure is less likely to be reversible in older women (in about 10 percent vs. up to 50 percent). The rate of permanent ovarian failure is lower with regimens of doxorubicin and cyclophosphamide than with cyclophosphamide, methotrexate and fluorouracil.

Heart disease: Caution should be used when treating patients with cyclophosphamide who have pre-existing heart disease.⁶

Pregnancy: FDA Pregnancy Category D.² There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Breastfeeding should be terminated prior to initiating cyclophosphamide therapy as this drug is excreted in breast milk.¹

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.¹⁴

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <i>bold, italics</i>	
allergy/immunology	anaphylactic reaction ¹⁵
	nasal congestion when IV doses are administered too rapidly (large doses via 30-60 minute infusion); ¹⁵ patients experience runny eyes, rhinorrhea, sinus congestion, and sneezing immediately after infusion ¹⁵ (1-10%)
blood/bone marrow/ febrile neutropenia	anemia
	methemoglobinemia with bone marrow transplant (BMT) doses ¹⁵
	<i>myelosuppression; WBC nadir 8-15 days, platelet nadir 10-15 days, recovery 17-28 days</i>
	thrombocytopenia
cardiovascular	<i>cardiac dysfunction in high-dose (<1%);¹⁵ high-dose can be defined as 60 mg/kg daily or 120-270 mg/kg over a few days;¹¹ manifests as CHF; cardiac necrosis or hemorrhagic myocarditis; pericardial tamponade (BMT doses)¹⁵</i>
coagulation	hypoprothrombinemia, risk of bleeding (very rare)
constitutional symptoms	asthenia or sweating (0.1-1%)
	dizziness ¹⁵ (<1%)
dermatology/skin	<i>extravasation hazard: none¹⁶</i>
	alopecia ^{7,15} (40-60%); begins 3-6 weeks after start of therapy
	facial flushing following IV administration ^{2,15} (1-10%)
	hyperpigmentation (skin and nails) ^{2,15} (<1%)
	rash, hives, or itching ^{2,15} (1-5%)
	redness, swelling, or pain at injection site ^{2,15}
	toxic epidermal necrolysis ¹⁵ (<1%)
endocrine	hyperglycemia ²
gastrointestinal	<i>emetogenic potential: >1g high moderate; <1g low moderate¹⁷</i>
	anorexia (33%)
	diarrhea ¹⁵ (>10%)
	hemorrhagic colitis ¹⁵ (<1%)
	mucositis ¹⁵ (>10%)
	myxedema or sore lips ² (0.1-11%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
	<i>nausea and vomiting are dose-related¹⁵: > 90% for >1500 mg/m², 60-90% for 750-1500 mg/m², 30-60% for ≤ 750 mg/m² or oral; usually beginning 6-10 hours after administration</i>
	stomatitis ^{2,15} (>10%)
hepatic	hepatotoxicity ¹⁵ (<1%)
	jaundice ¹⁵ (<1%)
metabolic/laboratory	hyperkalemia, usually in context of tumour lysis ¹⁵ (<1%)
	hyperuricemia with high-dose and/or long-term therapy ¹⁵ (<1%)
	syndrome of inappropriate antidiuretic hormone (SIADH) causing hyponatremia
pain	headache ^{2,15} (1-10%)
pulmonary	interstitial pulmonary fibrosis, with high-dose and/or long-term therapy ¹⁵ (<1%)
	pneumonitis, with high-dose and/or long-term therapy ¹⁵ (<1%)
renal/genitourinary	non-hemorrhagic cystitis ⁶
	<i>hemorrhagic cystitis (up to 40%)¹⁵; with high-dose and/or long term therapy²; severe, potentially fatal</i>
	renal tubular necrosis ¹⁵ (1-5%)
	hemorrhagic ureteritis (<1%)
secondary malignancy	urinary bladder, myeloproliferative, or lymphoproliferative malignancies ¹⁵ (<1%)
sexual/reproductive function	interferes with oogenesis and spermatogenesis ¹⁵ (>10%); may be irreversible in some patients; gonadal suppression (amenorrhea) ²
syndromes	syndrome of inappropriate antidiuretic hormone (SIADH) secretion with high-dose and/or long-term therapy ^{2,15} (1-5%)

Adapted from standard reference^{1,11} unless specified otherwise.

Cardiac toxicity may occur in patients receiving high-dose cyclophosphamide. High-dose can be defined as 60 mg/kg daily or 120-270 mg/kg over a few days.¹¹ Other risk factors for developing cardiac toxicity include previous chest or mediastinal radiotherapy, anthracycline administration, concomitant administration of chemotherapy drugs which are not normally considered cardiotoxic, especially carmustine, cytarabine, and 6-thioguanine,⁴ and by the presence of left ventricular dysfunction (ejection fraction less than 50%).¹⁸ The mechanism may involve direct injury to the endothelium by phosphoramidate mustard, an active metabolite of cyclophosphamide.^{18,19} Unlike anthracyclines, cyclophosphamide-induced cardiotoxicity does not appear to be cumulative.^{4,18,20} In contrast to anthracycline-induced cardiomyopathy which occurs months to years after cumulative doses of anthracyclines, cyclophosphamide-induced cardiotoxicity occurs much earlier.¹⁹ Toxicity has ranged from minor, transient ECG changes and asymptomatic elevation of cardiac enzymes at a total dose of 100 mg/kg to fatal myocarditis and myocardial necrosis at total doses ranging upwards from 144 mg/kg delivered over 4 days.⁴ Clinical signs include dyspnea, tachypnea, fluid retention, increased systemic venous pressure and shock.²¹ Patients may experience heart failure, arrhythmias, irreversible cardiomyopathy, pericarditis, or death as a result of cardiotoxicity.²¹ Treatment is supportive.⁴

Hemorrhagic cystitis may occur in up to 40% of patients (especially children) on long term or high dose cyclophosphamide therapy.^{6,11} Other risk factors for developing hemorrhagic cystitis include rate of infusion, and rate of metabolism of cyclophosphamide, as well as the hydration status, urine output, frequency of urination, and concurrent exposure to other urotoxic drugs or genitourinary radiotherapy.²² The mechanism may involve direct injury to the urothelium by acrolein, an active metabolite of cyclophosphamide.¹⁰ Hemorrhagic cystitis can develop within a few hours or be delayed several weeks.² Clinical diagnosis includes non-specific symptoms such as hematuria, dysuria, urgency and increased frequency of urination and can be confirmed using cystoscopy.²² Severe

hemorrhagic cystitis can lead to constriction of the bladder, anemia, recurrent urinary tract infection, bladder perforation, renal failure and death.²² Longterm complications include bladder fibrosis and contraction, urinary reflux and transitional cell bladder tumours. Non-hemorrhagic cystitis, edema of the bladder and suburethral bleeding can also occur.⁶

Prophylactic measures include encouraging patients to drink plenty of fluids during therapy (most adults will require at least 2 L/day), to void frequently, and to avoid taking the drug at night.¹⁵ Patients should be well hydrated before and for 24-72 hours following treatment.²² As well, cyclophosphamide should be administered as early in the day as possible to decrease the amount of drug remaining in the bladder overnight.² With large IV doses, IV hydration is usually recommended.¹⁵ The use of mesna and/or continuous bladder irrigation is rarely needed for doses $<2\text{g}/\text{m}^2$.¹⁵ However, mesna has been used in patients receiving cyclophosphamide for immunologically mediated disorders (e.g., Wegener's granulomatosis, systemic lupus erythromatosus, dermatomyositis, polyarteritis).¹¹ Further measures to reduce the incidence of cystitis include catheter bladder drainage, bladder irrigation, intravenous hydration with diuresis, hyperhydration, and the administration of mesna. Hyperhydration is generally not recommended as it places the patient at risk for fluid overload and electrolyte imbalance, particularly given the antidiuretic effect of cyclophosphamide.²² Diuretics may be indicated if urine production declines to $<100\text{ mL}/\text{m}^2/\text{h}$. It appears that mesna and hyperhydration are equally effective in preventing cyclophosphamide-induced cystitis in the BMT population.

Treatment of hemorrhagic cystitis^{11,22} begins with discontinuation of cyclophosphamide. Fluid intake should be increased and the platelet count should be maintained at $>50\,000/\text{mm}^3$ to minimize the extent of bleeding. There are several treatment options currently advocated, depending on the severity of bleeding.

Treatment of early cystitis²³:

- *The first line therapy* is to administer hyperhydration. Standard hyperhydration may consist of NS or 1/2 NS at a rate of $3.0\text{ L}/\text{m}^2$ per 24-hour period. Depending on the patient's electrolyte status, KCl and MgSO₄ are generally added to the fluid at concentrations 20-40 mEq/L and 2-4 g/L respectively. Patients who have visible clots in the urine, or have bladder spasms should receive continuous bladder irrigation. Treatment is generally continued for 48 hours after the urine returns to normal colour and the symptoms have resolved.
- *The second line therapy* is to initiate a bladder irrigation with Alum (aluminum potassium sulphate) which is prepared by pharmacy as a 1% solution for intravesical administration. This is instilled at a rate of 300-1000 mL/hour and the rate is adjusted to maintain clear pink drainage. Responses to Alum are improved following removal of clots in the bladder using either cystoscopy or irrigation prior to therapy. As Alum contains significant amounts of aluminum, aluminum levels should be taken in patients with renal impairment, or in patients requiring prolonged therapy.
- *The third line therapy* is with prostaglandin (carboprost) which is thought to stimulate platelet aggregation and cause local vasoconstriction. The dose is generally 0.8-1.0 mg/dL in 50 mL NS (400-500 mcg) instilled into the bladder; clamp catheter and allow solution to dwell for 60 minutes; repeat every six hours until response.²³ Like Alum, this therapy works best when the bladder is evacuated of clots before starting. Patients who respond will do so by 5-7 days. Carboprost can cause intense bladder spasm and this can be a major problem. Therapy with oxybutinin, Belladonna and opium suppositories, or systemic narcotic analgesics may be necessary. In rare cases, hemorrhagic cystitis is resistant to the above treatments and bladder fulguration with formalin or other chemicals is needed.

Treatment of late onset cystitis²³:

Many of these cases are due to secondary viral infection or bacterial infection of the injured mucosa. Culture for bacterial pathogens, cytomegalovirus (CMV) and adenovirus should be done before starting therapy. Primary therapy is hyperhydration, possibly with bladder irrigation. Patients may be need to be treated if pathogen is found (i.e., ganciclovir or foscarnet for CMV, ribavirin for adenovirus, antibiotics for bacterial infections).

Immunogenicity: Positive reactions to skin test antigens (e.g., tuberculin purified protein derivative, trichophyton, candida) are frequently suppressed in patients receiving cyclophosphamide.¹¹

Hyperuricemia may result from cell lysis by cytotoxic chemotherapy and may lead to electrolyte disturbances or acute renal failure.²⁴ It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas and myeloproliferative diseases. The risk may be increased in patients with pre-existing renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients²³:

- aggressive hydration: $3\text{ L}/\text{m}^2/24\text{ hr}$ with target urine output $>100\text{ mL}/\text{hr}$

- if possible, discontinuation of drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitoring of electrolytes, calcium, phosphate, renal function, LDH and uric acid q6h x 24-48 hours
- electrolyte replacement as required
- allopurinol 600 mg po initially, then 300 mg po q6h x 6 doses, then 300 mg po daily x 5-7 days.

Urine should be alkalinized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH > 7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalinization of the urine.²⁵ It may be used for treatment or prophylaxis of hyperuricemia, 0.2 mg/kg IV daily for up to 7 days; however, its place in therapy has not yet been established.

Interstitial pulmonary fibrosis^{11,26} may occur in patients receiving high doses of cyclophosphamide over prolonged periods. Other risk factors include exposure to other drugs with pulmonary toxicities and pulmonary radiotherapy. The mechanism may involve direct injury to the pulmonary epithelium by cyclophosphamide metabolites.²⁶ In some cases discontinuation of the drug and initiating corticosteroid therapy fails to reverse this condition, which can be fatal. Signs and symptoms typically include tachycardia, dyspnea, fever, non-productive cough, basilar crepitant rales, interstitial bilateral infiltrates on chest x-ray, hypoxemia and ventilation/perfusion dysfunction. Interstitial pneumonitis has also been reported in patients receiving cyclophosphamide. The drug should be stopped at the first sign of pulmonary toxicity; all other possible causes of pneumonitis should be ruled out.

Nasal stuffiness or facial discomfort may occur. This nasopharyngeal discomfort “wasabi nose” may be associated with rapid injection of cyclophosphamide.²⁷⁻²⁹ This reaction may be caused by a mucosal inflammatory response or possibly a cholinergic mechanism.³⁰ If troublesome for the patient, several interventions have been used³⁰: the slowing down of the infusion rate or giving as an intermittent infusion rather than as an IV bolus, the use of analgesics, decongestants, antihistamines, intranasal beclomethasone, or intranasal ipratropium.

Radiation recall reactions²: Cyclophosphamide has the potential to enhance radiation injury to tissues; this is a rare side effect. While often called radiation recall reactions, the timing of the radiation may be before, concurrent with, or even after the administration of the cyclophosphamide. Recurrent injury to a previously radiated site may occur weeks to months following the radiation.

SIADH (syndrome of inappropriate secretion of ADH)¹ may occur in patients receiving cyclophosphamide, resulting in hyponatremia, dizziness, confusion or agitation, unusual tiredness or weakness. This syndrome is more common with doses >50 mg/kg and may be aggravated by administration of large volumes of fluids to prevent hemorrhagic cystitis.⁸ The condition is self-limiting although diuretic therapy may be helpful in the situation when the patient has stopped urinating (especially if this occurs during the first 24 hours of cyclophosphamide therapy). Susceptible patients should be monitored for cardiac decompensation. If weight gain is excessive (1.5-2 kg) during hydration, the volume of IV fluid should be reduced.

Secondary malignancies¹ have developed in some patients, often several years after administration. The most frequently reported neoplasms are urinary bladder cancer, non-lymphocytic leukemia and non-Hodgkin's lymphoma. Urinary bladder malignancies generally have occurred in patients who previously had hemorrhagic cystitis.⁶

Water retention and dilutional hyponatremia: Administration of cyclophosphamide in doses higher than 30-40 mg/kg has been associated with water retention and dilutional hyponatremia.^{8,11} Children may be especially susceptible. The mechanism is related to direct injury to the distal renal tubules and collecting ducts by cyclophosphamide metabolites. Symptoms include decreased urine flow, decreased serum osmolality and sodium, and increased urine osmolality. These can occur 4 to 12 hours after cyclophosphamide and resolve within 20 to 24 hours after therapy.

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
allopurinol	delayed, moderate; increased myelosuppressive effects of cyclophosphamide is possible	unknown	frequent monitoring with a complete blood count may be required
amiodarone ³¹	increased risk of pulmonary fibrosis	unknown, possibly additive effect	avoid combination if possible; otherwise increase monitoring
chloramphenicol	delayed, moderate; decrease or delay in activation of cyclophosphamide	inhibition (weak) of the CYP2C8/9 and CYP3A4 enzymes by chloramphenicol ^{31,32}	standard monitoring procedures for both drugs
ciprofloxacin ³³	delayed, moderate; decreased antimicrobial effect of quinolone antibiotics is possible	decreased quinolone absorption by altering the intestinal mucosa	ciprofloxacin can be used as a prophylactic antibiotic in cyclophosphamide based regimens. ³⁴ consider monitoring ciprofloxacin therapy.
corticosteroids	decreased or increased effect of cyclophosphamide	induction (weak) of the CYP3A4 enzyme by corticosteroids ^{15,35-37}	clinical significance of this interaction is unlikely based on evidence available; observe for altered effect of cyclophosphamide.
digoxin	delayed, moderate; reduced serum levels of digoxin is suspected	drug-induced alterations of the intestinal mucosa may be involved	monitoring for reduced digoxin effect
grapefruit juice ³⁸	delayed, moderate; decreased or delayed activation of cyclophosphamide	inhibition (moderate) of the CYP3A4 enzyme ^{15,39} by grapefruit juice	avoid grapefruit juice for 48 hours before and on day of dose
hydrochlorothiazide ^{40,41}	myelosuppressive effects of cyclophosphamide may be increased	unknown	monitor for myelosuppression; consider alternative antihypertensive therapy
indapamide	delayed, moderate; prolonged leucopenia is possible	unknown	avoid concurrent use; consider alternative antihypertensive therapy
indomethacin ⁶	4 cases of severe pulmonary edema and acute life-threatening water intoxication	unknown	avoid concurrent use
phenytoin ⁹ , phenobarbital, rifampin and other drugs which induce CYP2B6 ⁴²	increased rate at which cyclophosphamide is converted to active and toxic metabolites and possibly to inactive metabolites	induction (strong) of the CYP2B6 enzyme ^{15,42} by phenytoin, phenobarbital and rifampin.	clinical significance of this interaction is unknown; observe for altered effect of cyclophosphamide

AGENT	EFFECT	MECHANISM	MANAGEMENT
succinylcholine	rapid, moderate; prolonged neuromuscular blockade produced by succinylcholine is probable	cyclophosphamide inhibits plasma cholinesterase resulting in decreased metabolism of succinylcholine	consider reducing succinylcholine based on measured plasma cholinesterase levels
warfarin	delayed, moderate; increased anticoagulant effect of warfarin suspected	inhibition of warfarin metabolism, or clotting factor synthesis	monitoring coagulation parameters during and after chemotherapy; adjust warfarin dose as needed

Adapted from standard reference³³ unless specified otherwise.

SUPPLY AND STORAGE:

Tablets⁶: Store at room temperature.

CYTOXAN® available as 25 mg and 50 mg white tablets with blue flecks.

PROCYTOX® available as 25 mg and 50 mg white to off-white, sugar-coated tablet.

Injection⁶: Store at room temperature.

CYTOXAN® available as a non-lyophilized formulation manufactured by Bristol-Myers Squibb;¹ available in single-use vials of 1000 mg and 2000 mg. Contains no preservative. Protect from light.

PROCYTOX® available as a non-lyophilized formulation⁴³ manufactured by Baxter; available in 200 mg, 500 mg, 1000 mg and 2000 mg vials. Contains no preservative. Protect from light.

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Compatibility: consult detailed reference

Additional information: Cyclophosphamide **oral suspension** may be prepared using the intravenous formulation. Reconstitute vials with normal saline to a concentration of 20 mg/mL. Withdraw vial contents and dilute 1:1 with suspending vehicle (simple syrup or ORA-PLUS®). Prepared suspensions in either suspending vehicle are stable 2 months in the refrigerator. When stored at room temperature, simple syrup preparations are stable 3 days and ORA-PLUS® preparations are stable 8 days.⁴⁴

PARENTERAL ADMINISTRATION:

BCCA administration guideline noted in **bold, italics**

Subcutaneous	no information found
Intramuscular	has been used
Direct intravenous	each 100 mg or fraction thereof over at least 1 minute
Intermittent infusion	in 50-100 mL of compatible IV solution over 20-60 minutes

BCCA administration guideline noted in **bold, italics**

Continuous infusion	the dose can be administered in a convenient volume
Intraperitoneal	has been used but not recommended due to need for metabolic activation ¹¹
Intrapleural	has been used but not recommended due to need for metabolic activation ¹¹
Intrathecal	no information found; metabolic activation required ¹¹
Intra-arterial	no information found
Intravesical	no information found

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count. Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

BCCA usual dose noted in **bold, italics**

Oral:	Cycle Length: 4 weeks ^{34,45}	100 mg/m² (range 75-100 mg/m²) once daily for 14 consecutive days (total dose per cycle 1400 mg/m²)
	3-4 weeks ⁴⁵ :	300 mg/m² (range 200-450 mg/m²) once daily for 5 consecutive days. (total dose per cycle 1500 mg/m² [range 1000-2250 mg/m²])

Round dose to the nearest 25 mg. The manufacturer recommends that the drug be taken on an empty stomach, but states it may be taken with food to decrease GI upset.⁵

Intravenous:	3 weeks ⁴⁶⁻⁴⁹	600 mg/m² (range 500-1000 mg/m²) for one dose on day 1
	4 weeks ⁵⁰ :	1000 mg/m² for one dose on day 1
	6 weeks ⁵¹ :	1200 mg/m² for one dose on day 1
	4 weeks ³⁴ :	525 mg/m² for one dose on day 1 and day 15 (total dose per cycle 1050 mg/m²)
	4 weeks ⁵² :	1200 mg/m² for one dose on day 1 and day 8 (total dose per cycle 2400 mg/m²)
	11 weeks ⁴⁸ :	1000 mg/m² for one dose on day 1 and day 56 (total dose per cycle 2000 mg/m²)

*High dose protocols with or without bone marrow transplant:
note: ideal body weight is often used.*

**60 mg/kg for one dose on day -3 and day -2⁵³
(total dose 120 mg/kg over 2 days)**

50 mg/kg for one dose on day -6, day -5 and day -4⁵⁴
(total dose 150 mg/kg over 3 days)

2700 mg/m² for one dose on day 1 and day 2⁵⁵
(total dose 5400 mg/m² over 2 days)

2500 mg/m² for one dose on day 1

1800 mg/m² once daily for five consecutive days starting on day -5⁵⁶
(total dose 7200 mg/m² over 4 days)

1800 mg/m² for one dose on day -6, day -5, day -4 and day -3^{57,58}
(total dose 7200 mg/m² over 4 days)

2000 mg/m² for one dose on day 3, day 4 and day 5⁵⁹
(total dose 6000 mg/m² over 3 days)

1000 mg/m² for one dose on day 1 and day 2⁶⁰
(total dose 2000 mg/m² over 2 days)

Concurrent radiation: infrequently radiation is given during treatment^{51,61}; more often given following chemotherapy^{34,62-68}

Dosage in myelosuppression: modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 "Dosage Modification for Myelosuppression"

Dosage in renal failure: Suggested dose modifications⁶⁹:

Creatinine clearance (mL/min)	Cyclophosphamide dose
≥ 10	100%
<10	75%

Calculated creatinine clearance = $\frac{N * (140 - \text{Age}) * \text{weight}}{\text{Serum Creatinine in } \mu\text{mol/L}}$

* For males N = 1.23; for females N = 1.04

Dosage in hepatic failure: no adjustment required

Dosage in dialysis: dialyzable with a high extraction efficiency⁷

hemodialysis: ½ dose has been suggested⁶⁹
there have been 2 case reports of giving high-dose cyclophosphamide with continuous bladder irrigation +/- mesna.^{70,71} Hemodialysis (duration 6 h) was performed 6 h⁷⁰ and 14 h⁷¹ after cyclophosphamide infusion. Dialysis should not be started sooner than 12 h after cyclophosphamide infusion.⁷²

chronic ambulatory peritoneal dialysis (CAPD): dose as for GFR < 10 mL/min/1.73m² (i.e., administer 75% of dose)⁷³

continuous arteriovenous or venovenous hemofiltration (CAVH): dose as for GFR 10-50 mL/min/1.73m² (i.e., administer 100% dose)⁶⁹

Children^{74,75}:

Cycle Length:

Oral:	daily:	50-300 mg/m ²
Intravenous:	3-4 weeks ⁷⁴	250-1800 mg/m ² for one dose on day 1, day 2, day 3 and day 4
	3-4 weeks ⁷⁵ :	up to 2000-3000 mg/m ² for one dose on day 1

REFERENCES:

1. Bristol-Myers Squibb Canada. Cyclophosphamide product monograph. Montreal, Canada; April 2004.
2. Cyclophosphamide. USP DI. Volume 1. Drug information for the health care professional. 20th ed. Englewood, Colorado: Micromedex, Inc.; 2002.
3. Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of Anticancer Drugs in Children. *Clinical Pharmacokinetics* 1987;12:179-182.
4. Perry MC. The Chemotherapy Source Book. Baltimore: Williams & Wilkins; 1992. p. 286-289.
5. Kinda Karra. Personal Communication. Associate, Medical Information and Drug Safety, Bristol-Myers Squibb Canada; 2005.
6. Repchinsky C, BSP. Compendium of Pharmaceuticals and Specialties. ; 2004. p. 1610-1613.
7. Balis F, Holcenberg JS, Bleyer WA. Clinical Pharmacokinetics of Commonly Used Anticancer Drugs. *Clinical Pharmacokinetics* 1983;8: 202-232.
8. Dorr RT, Von-Hoff DD. Drug monographs. Cancer chemotherapy handbook. 2nd ed. Norwalk, Connecticut: Appleton and Lange; 1994. p. 319-332.
9. de Jonge ME, Huitema ADR, van Dam SM, et al. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. *Cancer Chemother Pharmacol* 2004;55:507-510.
10. Miller LJ, Chandler SW, Ippoliti CM. Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins. *Annals of Pharmacotherapy*. 1994;28(5):590-4.
11. McEvoy GK. AHFS 2004 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2004. p. 948-952.
12. Cyclophosphamide. USP DI. Volume 1. Drug information for the health care professional. 20th ed. Englewood, Colorado: Micromedex, Inc.; 2000. p. 1155-1161.
13. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. *NEJM* 2001;344(26):1997-2008.
14. Tamara Shenkier. Personal communication. Medical Oncologist, BC Cancer Agency Vancouver Centre; 2005.
15. Rose BD editor. Cyclophosphamide: Drug Information. www.uptodate.com ed. Waltham, Massachusetts: UpToDate; 2005.
16. BC Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 1 February 2004.
17. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; May 1999.
18. Taniguchi I. Clinical Significance of Cyclophosphamide-induced Cardiotoxicity. *Internal Medicine* 2005;44(No. 2):89-90.
19. Kamezaki K, Fukuda T, Makino S, et al. Cyclophosphamide-induced Cardiomyopathy in a Patient with Seminoma and a History of Mediastinal Irradiation. *Internal Medicine* 2005;44(No 2):120-123.
20. Chanan-Khan A, Srinivasan S, Czuczman M. Prevention and Management of Cardiotoxicity from Antineoplastic Therapy. *J Support Oncol* 2004;2:251-266.
21. Angelucci E, Mariotti E, Lucarelli G, et al. Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. *Lancet*. 1992;339(8788):287-9.
22. West NJ. Prevention and treatment of hemorrhagic cystitis. *Pharmacotherapy*. 1997;17(4):696-706.
23. Leukemia/Bone Marrow Transplant Program of British Columbia. Leukemia/BMT Manual. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2003. p. 76-77.
24. DeVita VT, Hellman S, Rosenberg SA. *Cancer Principles & Practice of Oncology*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
25. Sanofi-Synthelabo. FASTURTEC® product information. Markham, Ontario; 2004.
26. Segura A, Yuste A, Cercos A, et al. Pulmonary fibrosis induced by cyclophosphamide. *Annals of Pharmacotherapy*. 2001;35(7-8):894-7.
27. Kosirog-Glowacki JL, Bressler LR. Cyclophosphamide-induced facial discomfort. *Ann Pharmacother* 1994;28(2):197-199.
28. Arena PJ. Oropharyngeal sensation associated with rapid intravenous administration of cyclophosphamide (NSC-26271). *Cancer Chemotherapy Reports - Part 1*. 1972;56(6):779-80.
29. Silberstein PT, Vercellotti GM. Facial burning from cyclophosphamide. *Cancer Treatment Reports*. 1984;68(7-8):1057.
30. Lo K, Aulakh AK, Gingerich KS, et al. Cyclophosphamide-induced nasopharyngeal discomfort (wasabi nose): a report of two cases. 2002; *J Oncol Pharm Practice*(8):131-134.

31. Bhagat R, Sporn TA, Long GD, et al. Amiodarone and cyclophosphamide: potential for enhanced lung toxicity. *Bone Marrow Transplantation*. 2001;27(10):1109-11.
32. Rose BD editor. Chloramphenicol: Drug Information. www.uptodate.com ed. Waltham, Massachusetts: UpToDate; 2005.
33. Tatro D editor. Drug Interactions Facts on Disc. St. Louis: Facts and Comparisons; 2004.
34. BC Cancer Agency Breast Tumour Group. BCCA protocol summary for adjuvant therapy for breast cancer using cyclophosphamide, epirubicin and fluorouracil (BRAJCEF). Vancouver: BC Cancer Agency; 2002.
35. Rose BD editor. Dexamethasone: Drug Information. www.uptodate.com ed. Waltham, Massachusetts: UpToDate; 2005.
36. Rose BD editor. Prednisolone: Drug Information. www.uptodate.com ed. Waltham, Massachusetts: UpToDate; 2005.
37. Rose BD editor. Prednisone: Drug Information. www.uptodate.com ed. Waltham, Massachusetts: UpToDate; 2005.
38. Repchinsky C, BSP. Compendium of Pharmaceuticals and Specialties. ; 2005. p. L74.
39. Rose BD. CYP3A4 Substrates/CYP3A4 Inhibitors (Moderate). UpToDate, 2005. Available at: www.uptodate.com. Accessed 25 August 2005.
40. Drug Facts and Comparisons® (database on the Internet). Cyclophosphamide. Wolters Kluwer Health Inc. Facts and Comparisons® eAnswers, updated periodically. Available at: <http://online.factsandcomparisons.com>. Accessed 17 August 2011.
41. MICROMEDEX® 2.0 Drug Interactions (database on the Internet). Cyclophosphamide. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at: <http://www.micromedex.com>. Accessed 17 August 2011.
42. Rose BD. CYP2B6 Substrates/CYP2B6 Inducers (Strong). UpToDate, 2005. Available at: www.uptodate.com. Accessed 25 August 2005.
43. Paul Agro BScPhm. Personal Communication. Agro Health Associates Inc.; 2005.
44. Kennedy R, Groepper D, Tagen M, et al. Stability of cyclophosphamide in extemporaneous oral suspensions. *Ann Pharmacother* 2010;44(2):295-301.
45. BC Cancer Agency Lymphoma Tumour Group. BCCA Protocol Summary for lymphoma palliative chemotherapy (LYPALL). Vancouver, British Columbia: BC Cancer Agency; 1 Nov 2002.
46. BC Cancer Agency Breast Tumour Group. BCCA Protocol summary for adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and fluorouracil (BRAJCAF). Vancouver: BC Cancer Agency; 2001.
47. BC Cancer Agency Breast Tumour Group. BCCA Protocol summary for adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide (BRAJAC). Vancouver: BC Cancer Agency; 2001.
48. BC Cancer Agency Lung Tumour Group. BCCA Protocol summary for treatment of extensive small cell lung cancer (SCLC) with cyclophosphamide, doxorubicin and vincristine (CAV) (LUCAV). Vancouver: BC Cancer Agency; 2002.
49. BC Cancer Agency Breast Tumour Group. BCCA Protocol summary for adjuvant therapy for premenopausal high risk breast cancer using cyclophosphamide, methotrexate and fluorouracil (BRAJCMF). Vancouver: BC Cancer Agency; 1999.
50. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone (LYCVP). Vancouver: BC Cancer Agency; 2002.
51. BC Cancer Agency Sarcoma Tumour Group. BCCA protocol summary for adjuvant therapy for patients with newly diagnosed Ewing's sarcoma/peripheral neuroectodermal tumour (PNET) or rhabdomyosarcoma using vincristine, doxorubicin and cyclophosphamide (SAVAC). Vancouver: BC Cancer Agency; 2002.
52. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for the treatment of Hodgkin's lymphoma using cyclophosphamide, vincristine and prednisone (LYCCOP). Vancouver: BC Cancer Agency; 2002.
53. Leukemia/Bone Marrow Transplant Program of British Columbia. Intensive therapy and autograft for Leukemia or Non-Hodgkin's lymphoma (BMT IV BUCY). BC Cancer Agency, 2003.
54. Leukemia/Bone Marrow Transplant Program of British Columbia. Intensive multimodal therapy and autologous BMT for non-Hodgkin's lymphoma (BMT LY 98-01). BC Cancer Agency, 2003.
55. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for the consolidation for lymphoma using etoposide, cyclophosphamide and vincristine (LYECV). Vancouver: BC Cancer Agency; 2002.
56. Leukemia/Bone Marrow Transplant Program of British Columbia. High-dose chemotherapy with autologous HSCT for high-risk nonseminomatous germ cell tumours (BMT 00-04). BC Cancer Agency, 2003.
57. Leukemia/Bone Marrow Transplant Program of British Columbia. Intensive multimodal therapy and hematopoietic progenitor cell transplantation for progressive Hodgkin's disease (BMT 88-01). BC Cancer Agency, 2000.
58. Leukemia/Bone Marrow Transplant Program of British Columbia. Intensive multimodal therapy and autograft for progressive Hodgkin's disease (HD-CBV 00-01). BC Cancer Agency, 2004.
59. Leukemia/Bone Marrow Transplant Program of British Columbia. High dose etoposide and cyclophosphamide salvage therapy for refractory acute leukemia (AL 91-02). BC Cancer Agency, 2004.
60. Leukemia/Bone Marrow Transplant Program of British Columbia. Treatment of Lymphoblastic lymphoma (NHL 98-01). BC Cancer Agency, 2004.
61. BC Cancer Agency Lung Tumour Group. BCCA protocol summary for treatment of limited stage small cell lung cancer (SCLC) alternating cyclophosphamide, doxorubicin and vincristine (CAV) with etoposide and cisplatin (EP) plus early thoracic irradiation (LUALTL). Vancouver: BC Cancer Agency; 2002.
62. BC Cancer Agency Breast Tumour Group. BCCA Protocol summary for Palliative Therapy for metastatic Breast Cancer using Doxorubicin and Cyclophosphamide (BRAVAC). Vancouver: BC Cancer Agency; 1999.
63. BC Cancer Agency Breast Tumour Group. BCCA Protocol summary for Inflammatory Breast Cancer using cyclophosphamide, doxorubicin and fluorouracil. (BRINFCAF). Vancouver: BC Cancer Agency; 2004.
64. BC Cancer Agency Breast Tumour Group. BCCA Protocol summary for Inflammatory Breast Cancer using cyclophosphamide, epirubicin and fluorouracil. (BRINFCEF). Vancouver: BC Cancer Agency; 2005.
65. BC Cancer Agency Breast Tumour Group. BCCA Protocol summary for Locally Advanced Breast Cancer using cyclophosphamide, doxorubicin and fluorouracil. (BRLA2). Vancouver: BC Cancer Agency; 2004.

66. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for the treatment of Lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone.(LYCHOP). Vancouver: BC Cancer Agency; 2005.
67. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for the treatment of Lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab.(LYCHOP-R). Vancouver: BC Cancer Agency; 2005.
68. BC Cancer Agency Sarcoma Tumour Group. (SAVAC+M) BCCA Protocol Summary for Vincristine, Adriamycin and Cyclophosphamide combination for patients with newly diagnosed Ewing's sarcoma/peripheral neuroectodermal tumour (PNET) and rhabdomyosarcoma with pelvic primaries or chemotherapy induced hematuria. SAVAC (r SAVAC+M is alternated with SAIME). Vancouver, British Columbia: BC Cancer Agency; 1 April 2003.
69. Aronoff GR, Berns JS, Brier ME, Golper TA, et al. Drug Prescribing in Renal Failure. 4th ed. ; 1999. p. 72-73.
70. Bischoff ME, Blau W, Wagner T, et al. Total body irradiation and cyclophosphamide in a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplantation 1998;22:591-593.
71. Perry JJ, Fleming RA, Rocco MV, et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis in acute leukemia and end-stage renal disease. Bone Marrow Transplantation 1999;23:839-842.
72. Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney International 2002;61:1495-1501.
73. Aronoff GR, Bennett WM, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing guidelines for adults and children. 5th ed. Philadelphia, Pennsylvania: American College of Physicians; 2007. p. 98.
74. Pizzo P, Poplack D. Principles and Practice of Pediatric Oncology. Fourth ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 246.
75. Pochedly C, editor. Neoplastic Diseases of Childhood. 1st ed. Chur, Switzerland: Harwood Academic Publishers; 1994. p. 218-220.